Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD
The Phase III AIRWARD™ trial was published today on ClinicalTrials.gov (NCT07907991).1 AIRWARD will evaluate the efficacy and safety of verducatib, an investigational oral therapy for COPD.1 The Phase III trial will enroll adults with symptomatic COPD who continue to experience exacerbations and have blood eosinophil counts below 300 cells/µL.1 Ingelheim, Germany and Ridgefield, Conn., U.S. […]
Read the full story at Financial PostOpen in the live monitor